New AMD drug completes Phase 2 trial
EyePoint

New AMD drug completes Phase 2 trial

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.